X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
0
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
The proceeds are expected to enable rapid expansion across multiple tumor types for the TNG908 and TNG462 PRMT5 programs, as well as maintain funding through proof-of-concept for each of its clinical-stage programs as the Company awaits clinical data.
Lead Product(s): TNG908
Therapeutic Area: Oncology Product Name: TNG908
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Nextech
Deal Size: $80.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement August 10, 2023
Details:
TNG908 is administered orally, a selective PRMT5 inhibitor that drives tumor regression, it is being developed for the treament of MTAP-deleted glioblastoma (GBM).
Lead Product(s): TNG908
Therapeutic Area: Oncology Product Name: TNG908
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2023
Details:
TNG908 is an investigational PRMT5 inhibitor with a novel MTA-cooperative binding mechanism designed to leverage the synthetic lethal interaction between PRMT5 inhibition and MTAP deletion.
Lead Product(s): TNG908
Therapeutic Area: Oncology Product Name: TNG908
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 19, 2022
Details:
TNG908, is a potent, synthetic lethal inhibitor of PRMT5 that works selectively in cells with MTAP deletion drives tumor regressions in MTAP-deleted xenograft models across multiple histologies.
Lead Product(s): TNG908
Therapeutic Area: Oncology Product Name: TNG908
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
TNG908, a potent, synthetic lethal inhibitor of protein arginine methyl transferase 5 inhibitor that selectively kills cancer cells with methylthioadenosine phosphorylase deletions, while sparing normal cells.
Lead Product(s): TNG908
Therapeutic Area: Oncology Product Name: TNG908
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2022
Details:
The proceeds are expected to provide Tango with the capital needed to further develop its pipeline, including ND filing for Tango’s lead program, TNG908; IND filing for its USP1 inhibitor; ND filing for an undisclosed target and Progressing multiple preclinical programs.
Lead Product(s): TNG908
Therapeutic Area: Oncology Product Name: TNG908
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: BCTG Acquisition Corp
Deal Size: $353.0 million Upfront Cash: Undisclosed
Deal Type: Acquisition April 14, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
